-+ 0.00%
-+ 0.00%
-+ 0.00%

Opko unit ModeX doses first patients in MDX2003 B-cell lymphoma trial

PUBT·04/22/2026 12:07:19
Listen to the news
Opko unit ModeX doses first patients in MDX2003 B-cell lymphoma trial
  • ModeX Therapeutics, an Opko Health unit, began a first-in-human Phase 1 trial with patient dosing for MDX2003 in relapsed or refractory B-cell lymphoma.
  • Study MDX-2003-101 (NCT07249905) will assess safety, tolerability, pharmacokinetics, immune activity.
  • MDX2003 is a tetraspecific T-cell engager targeting CD19, CD20, CD3, CD28.
  • Trial design includes dose-escalation, dose-expansion to set dosing for future efficacy studies.
  • ModeX presented preclinical data supporting dose selection at ASH 2025, ESMO Targeted Anticancer Therapies Congress 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opko Health Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604220800PRIMZONEFULLFEED9694204) on April 22, 2026, and is solely responsible for the information contained therein.